Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. It affects infancy, but it is also highly prevalent in adults and it is one of the disease burdens for the patients and their families. Nowadays, AD is recognized as a heterogenous disease with different subtypes with variable clinical manifestations which is affected by the impairments of the skin barrier. The severity of AD dictates the level of treatment. Current AD treatment focuses on restoration of the barrier function, mainly through the use of moisturizers and corticosteroids to control the inflammation, topical calcineurin inhibitors, and immunosuppresive drugs in the most severe cases. However, targeted disease-modifying therapies are under investigation. The most recent findings on the skin microbial dysbiosis is a promising future direction for the development of new treatments. We need to improve the understanding of the complex microbiome-host interactions, the role of autoimmunity, the comparative effectiveness of therapies and the ways to appropriately implement the educational strategies.

Atopic dermatitis : Recent insight on pathogenesis and novel therapeutic target / E. D'Auria, G. Banderali, S. Barberi, L. Gualandri, B. Pietra, E. Riva, A. Cerri. - In: ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY. - ISSN 0125-877X. - 34:2(2016 Jun), pp. 98-108. [10.12932/AP0732.34.2.2016]

Atopic dermatitis : Recent insight on pathogenesis and novel therapeutic target

E. D'Auria
;
L. Gualandri;B. Pietra;E. Riva
Penultimo
;
A. Cerri
Ultimo
2016-06

Abstract

Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. It affects infancy, but it is also highly prevalent in adults and it is one of the disease burdens for the patients and their families. Nowadays, AD is recognized as a heterogenous disease with different subtypes with variable clinical manifestations which is affected by the impairments of the skin barrier. The severity of AD dictates the level of treatment. Current AD treatment focuses on restoration of the barrier function, mainly through the use of moisturizers and corticosteroids to control the inflammation, topical calcineurin inhibitors, and immunosuppresive drugs in the most severe cases. However, targeted disease-modifying therapies are under investigation. The most recent findings on the skin microbial dysbiosis is a promising future direction for the development of new treatments. We need to improve the understanding of the complex microbiome-host interactions, the role of autoimmunity, the comparative effectiveness of therapies and the ways to appropriately implement the educational strategies.
anti-inflammatory therapies; atopic dermatitis; biologics; dietary factors; skin barrier; Skin microbioma; immunology and allergy; immunology; medicine (all)
Settore MED/35 - Malattie Cutanee e Veneree
Article (author)
File in questo prodotto:
File Dimensione Formato  
asianpacific.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.01 MB
Formato Adobe PDF
1.01 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/465038
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 38
  • ???jsp.display-item.citation.isi??? 32
social impact